Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials

ClinicalLIVEUpdated 18 Nov 2026

New Clinical Trials

Clinical trials companies registered in the last 30 days, worldwide, with the sponsor, phase and countries.

Sources: ClinicalTrials.gov · Rebuilt weekly · Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase.

Trials
777
in the 30 days to 2026-11-18
Added in 30 days
777
to 18 Nov 2026
Top country
United States
192 · 25% of the list
Phase covered
8
distinct values
Snapshot · 18 Nov 2026
Explore all 777

Signals

What the register says this week, and why it matters if you sell into it.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
  3. 174 of the listed studies are device, diagnostic or digital-health studies (no drug phase).
  4. A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

Export the full new clinical trials

777 rows as a .csv. Free. Every field, with its source link.

Country
Phase 1
Study type
208 / 777 trials
PostedSponsorStudyPhaseStatus
5 Nov 2026Gan & Lee Pharmaceuticals.ChinaComparison of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of GZR101-80 Injection With Separately Injected, Simultaneous Doses of GZR33 Injection and Insulin AspartPhase 1Recruiting5 Nov 2026Jiangsu Chuangyuan Life Science and Technology Co., Ltd.ChinaCPU-YL01 Injection in Patients With Chronic Hepatitis B.Phase 1Enrolling By Invitation5 Nov 2026Kyorin Pharmaceutical Co.,LtdCanadaA Study to Evaluate the Effects of Therapeutic and Supratherapeutic Doses of KRP-S124 Compared to Placebo With Moxifloxacin on QTc Interval in Healthy ParticipantsPhase 1Recruiting5 Nov 2026Merck Sharp & Dohme LLCA Clinical Trial of MK-7602 in Healthy Volunteers (MK-7602-006)Phase 1Not Yet Recruiting5 Nov 2026ModernaTX, Inc.UgandaA Study to Investigate the Safety and Immunogenicity of mRNA-1469 in African Participants 1 to 65 Years of AgePhase 1Not Yet Recruiting5 Nov 2026ModernaTX, Inc.United KingdomA Study to Investigate the Safety, Reactogenicity, and Immunogenicity of a Preventative Vaccine for Marburg Virus (mRNA-1519) in Healthy Adult ParticipantsPhase 1Not Yet Recruiting4 Nov 2026Antlia Bioscience, IncNew ZealandStudy of AB-110 in Healthy and Hypertensive ParticipantsPhase 1Not Yet Recruiting4 Nov 2026Basilea PharmaceuticaUnited StatesA Study to Test the Safety of the Study Drug Fosmanogepix and How the Body Handles It in Adults With Severe Kidney Failure on DialysisPhase 1Recruiting4 Nov 2026Beijing Gene Key Life Technology Co., LtdChinaA Study of GKL-006Allo Injection in Patients With Ankylosing SpondylitisPhase 1Not Yet Recruiting4 Nov 2026Beijing QL Biopharmaceutical Co.,LtdChinaA Study of Zovaglutide (ZT002 Injection) in Participants With Hepatic Impairment and Healthy ParticipantsPhase 1Not Yet Recruiting4 Nov 2026Eli Lilly and CompanySingaporeA Study of Lepodisiran (LY3819469) in Participants With High Lipoprotein(a)Phase 1Recruiting4 Nov 2026Eli Lilly and CompanyUnited States, SingaporeA Study of LY4247147 in Participants With Obesity or Overweight Who Are Otherwise HealthyPhase 1Recruiting4 Nov 2026Haisco Pharmaceutical Group Co., Ltd.ChinaPhase 1 Study to Assess the Effects of HSK31858 on the QT/QTc Interval in Healthy Chinese ParticipantsPhase 1Recruiting4 Nov 2026Haisco Pharmaceutical Group Co., Ltd.ChinaInvestigation of Pharmacokinetics, Safety of HSK31858 in Subjects With Renal ImpairmentPhase 1Recruiting4 Nov 2026Latigo BiotherapeuticsLTG-321 - Itraconazole Drug-drug Interaction (DDI) StudyPhase 1Not Yet Recruiting4 Nov 2026Luminance Biosciences IncAustraliaSafety and Biodistribution of [68Ga]Ga DOTA-5G in Subjects With Metastatic Breast Cancer (BC)Phase 1Not Yet Recruiting4 Nov 2026Shanghai Qilu Pharmaceutical Research and Development Center LTDA Study of QLS5314 Monotherapy in Participants With Advanced Solid TumorsPhase 1Not Yet Recruiting3 Nov 2026Beijing InnoCare Pharma Tech Co., Ltd.Safety, Tolerability and Pharmacokinetics of ICP-B161 in Healthy Adults VolunteersPhase 1Not Yet Recruiting3 Nov 2026Haisco Pharmaceutical Group Co., Ltd.ChinaInvestigation of Pharmacokinetics, Safety of HSK31858 in Subjects With Hepatic ImpairmentPhase 1Recruiting3 Nov 2026Hunan Kelun Pharmaceutical Co., Ltd.ChinaA Study to Evaluate the PK/PD and Safety of KL0011034 Injection in Healthy Non-Elderly and Elderly Trial ParticipantsPhase 1Not Yet Recruiting3 Nov 2026Jiangsu Simcere Pharmaceutical Co., Ltd.ChinaStudy of SIM0518 in Participants With ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung CancerPhase 1Not Yet Recruiting3 Nov 2026Leukos Biotech S.L.SpainEvaluation of LB-208 (HTR1B Antagonist) in Adult Patients With Relapsed or Refractory Solid Tumours and LymphomaPhase 1Recruiting3 Nov 2026Mabwell (Shanghai) Bioscience Co., Ltd.ChinaPhase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood CancersPhase 1Recruiting3 Nov 2026Royan Stem Cell Technology CompanyIranARTEMIS: Umbilical Cord-Derived Mesenchymal Stromal Cells (UC-MSCs) After Mechanical Thrombectomy for Acute Ischemic StrokePhase 1Not Yet Recruiting3 Nov 2026Yuhan CorporationSouth KoreaBioequivalence Study Between YHP2508A and YHR2601 in Healthy SubjectsPhase 1Recruiting3 Nov 2026Yuhan CorporationSouth KoreaBioequivalence Study Between YHP2508B and YHR2602 in Healthy SubjectsPhase 1Recruiting2 Nov 2026AmgenUnited StatesComparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)Phase 1Recruiting2 Nov 2026AmgenComparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release FormulationPhase 1Not Yet Recruiting2 Nov 2026AstraZenecaUnited KingdomA Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234Phase 1Not Yet Recruiting2 Nov 2026JemincareA Study to Investigate the Pharmacokinetics of JMKX003142 in Healthy Participants and Participants With Hepatic ImpairmentPhase 1Not Yet Recruiting2 Nov 2026Kanvas BiosciencesUnited States, CanadaA Phase 1 Trial of KAN-001 With Pembrolizumab, With or Without Chemotherapy, in Participants With PD-L1-Positive Non-Small Cell Lung CancerPhase 1Not Yet Recruiting2 Nov 2026Medicovestor, IncUnited StatesA Study of MC001 in Patients With Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) and Other Folate Receptor Alpha (FRα)-Expressing Solid TumorsPhase 1Not Yet Recruiting2 Nov 2026Nanjing Chia-tai Tianqing PharmaceuticalChinaA Phase 1 Clinical Trial of NTQ6179 Tablets in Healthy VolunteersPhase 1Recruiting2 Nov 2026Novartis PharmaceuticalsUnited StatesA Study to Assess the Safety, Tolerability and Pharmacokinetics of XEP527 in Patients With Stable SchizophreniaPhase 1Recruiting2 Nov 2026Novartis PharmaceuticalsIsraelA Study of TRB191 in Patients With Extensive-stage Small Cell Lung CancerPhase 1Recruiting2 Nov 2026SunGlow Innovations LLCIntratumoral Chlorine Dioxide Injection in Advanced Solid TumorsPhase 1Not Yet Recruiting30 Oct 2026Boehringer IngelheimGermanyA Study to Test How Well Different Doses of BI 3821001 Are Tolerated by Healthy PeoplePhase 1Recruiting30 Oct 2026Hoffmann-La RocheA Study to Evaluate the Safety and Effectiveness of Different Doses of RO7836748 Alone or in Combination With Other Cancer Therapies in People With Solid Tumors With a Rat Sarcoma Viral Oncogene Homolog Glycine 12 Valine (RAS G12V) MutationPhase 1Not Yet Recruiting30 Oct 2026Immunis, Inc.Safety and Tolerability of Single and Repeated Dose of IMM02-KORA in PD-associated DyskinesiaPhase 1Not Yet Recruiting30 Oct 2026Neurelis, Inc.Study to Establish Safety, Tolerability and Pharmacokinetics of NRL-1049 in Healthy Adult Participants Following Multiple-Dose AdministrationPhase 1Not Yet Recruiting30 Oct 2026Sachi Bioworks Inc.United StatesA Study of Single Ascending Doses of NI112 in Adults With Amyotrophic Lateral Sclerosis (ALS)Phase 1Not Yet Recruiting30 Oct 2026Shanghai Hengrui Pharmaceutical Co., Ltd.ChinaA Study to Assess the Effect of Itraconazole on the Pharmacokinetics of HRS-4642 Following Intravenous Infusion in Healthy ParticipantsPhase 1Not Yet Recruiting30 Oct 2026Shanghai Qilu Pharmaceutical Research and Development Center LTDA Phase 1 Study of QLS2416 Injection in Participants With Autoimmune DiseasesPhase 1Not Yet Recruiting30 Oct 2026Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. LtdChinaA Mass Balance Study on [14C]Levornidazole Disodium Phosphate for Injection in Healthy Chinese Adult Male SubjectsPhase 1Completed30 Oct 2026Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. LtdChinaPharmacokinetics and Safety of Levornidazole Disodium Phosphate for Injection in Chinese Patients With Hepatic ImpairmentPhase 1Completed29 Oct 2026Beeline Medicines CorporationAustraliaA Phase 1, First-in-Human Trial of BLN-481in Healthy Adult ParticipantsPhase 1Recruiting29 Oct 2026BeOne MedicinesA Study of BON-C1393 in Adults With Advanced Solid TumorsPhase 1Not Yet Recruiting29 Oct 2026Cibus Therapeutics, Inc.AustraliaA Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of CBT-248 in Healthy Adult ParticipantsPhase 1Recruiting29 Oct 2026Elixiron Immunotherapeutics Inc.TaiwanA Phase 1, Open-Label, Two-Stage, Food Effect Study to Assess the Safety, Tolerability, and Pharmacokinetics of EI-1071 Under Fasted or Fed Conditions in Healthy VolunteersPhase 1Not Yet Recruiting29 Oct 2026GlaxoSmithKlineA Study to Compare Blood Levels of Bepirovirsen and Safety Using Different Methods of Injecting in Healthy Adult ParticipantsPhase 1Not Yet Recruiting

// How AOS uses this

Every row here is a potential account. AOS finds the ones that need what you sell, maps the decision makers and prepares the outreach for your approval.